The Australian cannabis sector must put clinical research and product innovation at its core as it enters a new phase of growth and maturity, according to senior business leaders.
But it must also tackle familiar issues that continue to hamper progress and frustrate local producers.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
This is a fantastic article with innovation being the key to differentiation. For example, innovative technologies such as water encapsulated nano-technology cannabinoids are now on market in US with studies highlighting exceptional bioavailability, shelf stability, biosolubility and clinical efficacy. The speed of our entire local ecosystem is required to ensure patients can have access to such products.
The problem is that the legislation is angled at pharmaceutical processes which are generally built for mass-scale substances. Ones that are proven to induce metabolic processes in majorities of individuals to produce more or less of some specific signalling compound used in the nervous systems of the human body.
That does not lend itself well to the personalised medicines that cannabis offers – cannabis based medicines are not easily engineered for specific effect on wide-ranging populations. The patient themselves must decide their medicine; a prescription for a specific amount of substance and nothing but is exactly the issue that is preventing cannabis-based medicines from truly taking hold in the market.